Experienced in Squamous Cell Lung Carcinoma

Dr. Anna B. Belcheva

Oncology | Hematology Oncology
Texas Oncology PA
13215 Dotson Rd, Suite 300, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Squamous Cell Lung Carcinoma
Texas Oncology PA
13215 Dotson Rd, Suite 300, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anna Belcheva is an Oncologist and a Hematologist Oncology provider in Houston, Texas. Dr. Belcheva is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, and Inflammatory Breast Cancer. Dr. Belcheva is currently accepting new patients.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Tops Surgical Specialty Hospital
Hca Houston Healthcare Tomball
Hca Houston Healthcare Kingwood
Houston Methodist Willowbrook Hospital
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
13215 Dotson Rd, Suite 300, Houston, TX 77070

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Device, Other
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drug: Hydroxytyrosol
Study Phase: Phase 2/Phase 3
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

5 Total Publications

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
Journal: Science translational medicine
Published: December 15, 2021
Similar Doctors
Distinguished in Squamous Cell Lung Carcinoma
Dr. Syed H. Jafri
Hematology Oncology | Oncology | Hematology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Syed H. Jafri
Hematology Oncology | Oncology | Hematology

UT Physicians

17500 W Grand Pkwy S, 
Sugar Land, TX 
 (28.8 miles away)
281-725-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Syed Jafri is a Hematologist Oncology specialist and an Oncologist in Sugar Land, Texas. Dr. Jafri is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Jafri is currently accepting new patients.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Jianjun J. Zhang
Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Jianjun J. Zhang
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (20.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jianjun Zhang is an Oncologist in Houston, Texas. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Metastatic Pleural Tumor, Non-Small Cell Lung Cancer (NSCLC), and Hip Replacement.

Distinguished in Squamous Cell Lung Carcinoma
Dr. John V. Heymach
Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. John V. Heymach
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (20.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Heymach is an Oncologist in Houston, Texas. Dr. Heymach is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Belcheva's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 67 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile